Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All at-risk groups, and people with HIV in particular, should therefore receive the second dose of the vaccine as recommended. The results of the study have now been published in The Lancet Infectious Diseases.
Single vaccine dose shows 84% effectiveness against mpox, but insufficient for HIV patients
